Janux Therapeutics, Inc. (NASDAQ:JANX) is RA Capital Management L.P.'s 3rd Largest Position

RA Capital Management L.P. boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,365,652 shares of the company's stock after acquiring an additional 1,200,000 shares during the period. Janux Therapeutics accounts for about 7.3% of RA Capital Management L.P.'s investment portfolio, making the stock its 3rd largest holding. RA Capital Management L.P. owned about 19.75% of Janux Therapeutics worth $554,977,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Russell Investments Group Ltd. increased its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. Avanza Fonder AB bought a new stake in Janux Therapeutics in the 4th quarter worth about $139,000. Meeder Asset Management Inc. purchased a new position in Janux Therapeutics in the 4th quarter worth about $159,000. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after acquiring an additional 3,436 shares during the period. Finally, Chicago Capital LLC purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $230,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $3.96 during mid-day trading on Tuesday, hitting $25.83. The stock had a trading volume of 1,199,629 shares, compared to its average volume of 969,626. The firm's 50 day moving average is $29.74 and its 200 day moving average is $42.33. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -22.08 and a beta of 3.24. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on JANX shares. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush restated an "outperform" rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Finally, Scotiabank reduced their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $95.25.

Insider Activity at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,001 shares of company stock worth $313,964. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.